RIPE-KG · Version 1.1.0 · Resource
ripekg:work/10.1002%2Fajh.25632
https://w3id.org/ripe/ripe-kg/work/10.1002%2Fajh.25632
| Subject | Predicate | Object |
|---|---|---|
ripekg:work/10.1002%2Fajh.25632Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux |
prism:doi |
10.1002/ajh.25632 |
ripekg:work/10.1002%2Fajh.25632Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux |
dcterms:title |
Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux |
ripekg:work/10.1002%2Fajh.25632Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux |
rdf:type |
node1 |
ripekg:work/10.1002%2Fajh.25632Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/10.1002%2Fajh.25632Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux |
rdf:type |
rdfs:Resource |
ripekg:work/10.1002%2Fajh.25632Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux |
rdf:type |
owl:Thing |
ripekg:work/10.1002%2Fajh.25632Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux |
rdf:type |
prov:Entity |
ripekg:work/10.1002%2Fajh.25632Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux |
rdf:type |
ripe:WorkWork |
ripekg:work/10.1002%2Fajh.25632Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux |
owl:sameAs |
https://semopenalex.org/work/W2972154418 |
ripekg:work/10.1136%2Fbmj-2025-084314Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial |
http://purl.org/spar/cito/cites |
ripekg:work/10.1002%2Fajh.25632Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux |